JonesTrading Upgrades Monopar Therapeutics to Buy, Announces $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
JonesTrading analyst Soumit Roy upgrades Monopar Therapeutics (MNPR) from Hold to Buy with a $2 price target.

April 11, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Monopar Therapeutics was upgraded by JonesTrading from Hold to Buy with a new price target of $2.
Upgrades by analysts, especially from Hold to Buy, typically lead to positive short-term price movements as they reflect a positive change in the stock's outlook. The new price target of $2 suggests a significant upside potential from current levels, which can attract more investors to the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100